Dilizem

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dilizem

Property Description
Active ingredient Diltiazem hydrochloride
Form Tablet, Extended-release capsule, Injection
Pharmacological class Calcium Channel Blocker (Non-dihydropyridine)
Common use Cardiovascular agent
Origin Synthetic (Benzothiazepine derivative)

Dilizem is a synthetic prescription medicine whose active compound is Diltiazem hydrochloride, classified as a non-dihydropyridine Calcium Channel Blocker (CCB). This core classification establishes it as a Benzothiazepine derivative, a specialized chemical structure used in cardiovascular medicine. The core classification as a CCB means the medicine works by modulating the movement of calcium ions, a fundamental action that is widely clinically recognized for its therapeutic effects on the heart and blood vessels.


What is the Composition and Pharmacological Class of Dilizem?

The composition of Dilizem centers on the active substance Diltiazem hydrochloride, which places the medicine within the Calcium Channel Blocker class. This classification is vital, as it means the medicine works by modulating the movement of calcium ions into cardiac and vascular smooth muscle cells. This action primarily helps the heart and blood vessels relax, easing the system's workload. As a synthetic compound, Diltiazem is a single-ingredient product.


Forms, Origin, and General Purpose

The general purpose of Dilizem is to provide therapeutic benefit by easing the strain on the cardiovascular system through controlled vasodilation and regulation of cardiac rhythm. It is available for both oral and intravenous route of administration, presenting in several dosage forms, including the standard tablet, the extended-release capsule for prolonged action, and a solution for injection. The drug's availability in multiple forms allows it to be used flexibly, for instance, in managing situations where rapid cardiac rhythm control is necessary.


How Does Diltiazem Differ from Other Calcium Channel Blockers?

Diltiazem is functionally distinct from many other CCBs because it is a non-dihydropyridine agent, giving it a balanced effect on both vascular resistance and heart rhythm. The anti-arrhythmic properties of Diltiazem alongside its vasodilating effects are widely accepted within medical guidelines. This dual mechanism is beneficial because it helps manage both the force of contractions and the speed of the heart's electrical signals simultaneously, distinguishing its general benefit from agents that primarily focus on vessel widening alone.

What side effects are possible with Dilizem?

Dilizem: Possible side effects and safety information

Adverse Reactions and Safety Profile

Dilizem (diltiazem) is associated with a range of adverse reactions, which are classified by regulatory authorities based on system-organ class and frequency. The most common adverse effects include peripheral edema (swelling of the lower limbs), headache, dizziness, fatigue, and bradycardia (slow heart rate), as well as gastrointestinal issues like nausea and constipation. Dermatological reactions such as rash and flushing are also common.

Serious and Clinically Significant Adverse Reactions

The most clinically significant risks relate to the drug's effect on cardiac conduction and function. Serious adverse reactions, though less common, include second- or third-degree AV block, sick sinus syndrome exacerbation, pronounced hypotension, and congestive heart failure, particularly in patients with pre-existing impaired ventricular function. Acute hepatic injury (liver damage), generally reversible upon discontinuation, and severe skin reactions like Stevens-Johnson syndrome and toxic epidermal necrolysis have also been documented.

Contraindications and Safety Restrictions

Dilizem is strictly contraindicated in individuals with:

  • Sick sinus syndrome (unless a functioning ventricular pacemaker is present).
  • Second- or third-degree AV block (unless a functioning ventricular pacemaker is present).
  • Severe hypotension.
  • Acute myocardial infarction with pulmonary congestion.
  • Documented hypersensitivity to the drug.

Caution and close observation are required in patients with pre-existing conditions such as reduced left ventricular function, hepatic impairment, or renal impairment. Regulatory labeling states that the safety and efficacy of diltiazem use have not been established in pediatric patients.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Diltiazem hydrochloride (Dilizem) is officially documented to result from an exaggerated extension of its effects, primarily impacting the cardiovascular system. Manifestations include severe hypotension (low blood pressure) and bradycardia (abnormally slow heart rate). The official labeling identifies severe, potentially life-threatening outcomes, including high-degree Atrioventricular (AV) block, cardiac failure, and cardiogenic shock.

Regulatory authorities mandate that individuals must seek immediate emergency medical attention upon the suspicion of overdose. Patients and caregivers are required to contact the Poison Help line or equivalent local services immediately.

Overdose management is explicitly symptomatic and supportive, as no specific antidote is known for Diltiazem. Treatment procedures specified in regulatory documents include gastric lavage and activated charcoal (if appropriate), alongside specific pharmacological measures such as administration of Atropine, vasopressors, or inotropic agents to stabilize severe hemodynamic effects. Continuous hospital monitoring is required, and cardiac pacing may be necessary for fixed high-degree AV block. Overdose involving sustained-release formulations may require prolonged observation due to the risk of delayed toxicity.

Therapeutic Uses of Dilizem

What Dilizem Treats: Main Uses and Benefits

Dilizem is relevant for symptomatic relief in cardiovascular conditions involving both vascular stress and abnormal heart rhythm. The medication is generally prescribed to help with high blood pressure, address angina (chest pain), and manage specific types of arrhythmias (irregular heart rhythms). It is applied across domains where additional symptomatic support is needed and where symptoms create noticeable interference with daily stability.


Therapeutic Applications and Benefits

Dilizem is relevant in conditions characterized by persistent systemic hypertension, and is used for symptom relief in Angina Pectoris (including chronic stable and vasospastic forms). The medication may assist patients with easing the overall symptom load related to chest pain and discomfort. It is also applied for rate control in supraventricular tachyarrhythmias, contributing to easing distressing manifestations of a chaotic heart rhythm.

“It is relevant in contexts involving heightened systemic burden, where short-term symptomatic assistance is needed.”


Quick Fact: Support for Cardiac Rhythm

Quick Fact: Support for Rapid Heartbeat. Dilizem is relevant for managing rapid ventricular rates, contributing to easing distressing manifestations of a chaotic heart rhythm.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Dilizem?

Eligibility for Dilizem (Diltiazem hydrochloride) is strictly defined by regulatory authorities, focusing on a patient's cardiac function and hemodynamic status. The medicine is contraindicated (must not be used) for several populations due to the potential for serious complications.


Absolute Contraindications

Use is prohibited for patients with:

  • Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a functioning ventricular pacemaker is present).
  • Severe Hypotension (e.g., systolic pressure less than 90 mmHg) or Cardiogenic Shock.
  • Severe Bradycardia (e.g., pulse below 40–50 beats per minute).
  • Acute Myocardial Infarction with Pulmonary Congestion or Atrial Fibrillation/Flutter associated with an accessory bypass tract.
  • Known hypersensitivity to the drug or its excipients.

Population and Condition Restrictions

  • Pediatric Population: Safety and efficacy have not been established; use is not recommended in children.
  • Older Adults: Use is permitted, but caution is required, and close monitoring may be necessary due to potential age-related organ function changes.
  • Organ Impairment: Patients with Hepatic or Renal Impairment must use the medicine with caution as drug clearance may be altered.
  • Lactation: The drug is excreted in human milk, and lactation is cited as a contraindication in some official labeling.

What should I know about interactions with other medicines?

Dilizem’s interaction profile is established by regulatory documents based on its influence over the CYP450 3A4 metabolic enzyme and its pharmacodynamic cardiosuppressive effects. Co-administration with certain substances is formally contraindicated due to the risk of increased exposure. Medicines such as Flibanserin and Lomitapide are prohibited because Dilizem's inhibition of CYP3A4 significantly raises their plasma concentrations. The intravenous form of Dilizem is contraindicated with intravenous beta-blockers due to the potential for additive effects on cardiac function.

Many other medicinal products require close monitoring. Dilizem is a documented inhibitor of CYP3A4 and P-glycoprotein, which leads to increased systemic exposure of co-administered substrates like Midazolam and Triazolam, often resulting in a three- to four-fold increase in their plasma levels. This effect also mandates an official restriction on the maximum daily dose of co-administered Simvastatin in regulatory documents. Furthermore, Dilizem has additive pharmacodynamic effects with drugs that slow the heart rate, including Digoxin and oral beta-blockers, increasing the risk for prolonged AV conduction. The extended-release form of the medicine has a specific restriction: co-ingestion with alcohol may result in a more rapid absorption and increase in systemic exposure. Caution is also warranted regarding interactions in patients with impaired renal or hepatic function.

Mechanism of Action

The mechanism of Dilizem is centered on the selective inhibition of the voltage-dependent L-type Calcium Channel (CaV1.2), a core biological target found across the cardiovascular system. This action fundamentally reduces the influx of calcium ions (Ca^2+) into cardiac and vascular cells, and affects specific physiological processes.

Modulation of Cardiac Electrical Conduction

This domain covers the drug's effect on the heart's intrinsic electrical system, specifically the Sinoatrial (SA) node and the Atrioventricular (AV) node. By reducing calcium influx in these areas, the drug imposes a negative chronotropy (slowing of heart rate) and a negative dromotropy (slowing of electrical signal transit time), which results in altered signal propagation and intrinsic firing frequency.

Control of Myocardial Force and Vascular Tone

This domain addresses the mechanical consequences of calcium blockade on the heart muscle and blood vessels. In cardiac myocytes, the mechanism causes a negative inotropy (decreased force of contraction), while in arterial smooth muscle, it induces vasodilation (widening of vessels), resulting in decreased myocardial mechanical effort and decreases the overall Systemic Vascular Resistance (SVR).

Dosage and Administration Information

How to Use Dilizem: Administration Guidelines

This section outlines the instructions for the use of Dilizem (diltiazem hydrochloride).


Administration Protocol

Feature Guideline
Route of Administration The medicine is administered via the Oral route (tablets and capsules) and the Intravenous (IV) route (injection or infusion).
Dosing Schedule Oral ER Forms (for hypertension/angina) typically start at 120 mg to 240 mg once daily, with a maximum daily dose up to 540 mg. Oral IR Tablets (for angina) are generally taken in three or four divided doses per day.
Frequency and Titration Oral doses are usually administered once daily (ER forms) or multiple times per day (IR forms). Dose adjustments for chronic oral therapy are generally recommended at intervals of 7 to 14 days.
Preparation & Intake Extended-release tablets and capsules must be swallowed whole and must not be crushed or chewed. Immediate-release tablets are typically taken before meals and at bedtime

Procedural and Population Constraints

Constraint Guideline
IV Administration The initial bolus dose must be administered precisely over a period of 2 minutes. Continuous intravenous infusion is generally limited to a maximum duration of 24 hours.
Missed Dose Rule If a dose is missed, the guideline is to take the next dose at the regularly scheduled time and not to take two doses simultaneously.
Age-Group Rule Older adults require caution and may need a lower starting dose with slow titration. Safety and efficacy have not been established for the pediatric population.

Connection to the Overall Use Protocol

These instructions establish a structured protocol that defines the appropriate route, dose limits, frequency, and special handling for Dilizem. This framework ensures the medicine is administered within defined boundaries, differentiating between chronic oral use and acute intravenous use.

Recent Clinical Evidence

Dilizem: Recent Clinical Evidence

Clinical research on diltiazem (marketed under various names including Dilizem) focuses primarily on its established indications: hypertension, chronic stable angina, and certain supraventricular arrhythmias. Studies consistently investigate its mechanism as a nondihydropyridine calcium channel blocker that affects both vascular smooth muscle and cardiac conduction.


Summary of Key Trial Types

Study Type Primary Focus Evaluated
Randomized Controlled Trials (RCTs) Efficacy in lowering blood pressure and increasing exercise tolerance in chronic stable angina compared to placebo.
Pharmacodynamic Studies Effects on atrioventricular (AV) nodal conduction time and refractoriness, which is linked to its use in controlling rapid heart rates.
Observational/Case Studies Investigational uses, such as topical application for chronic anal fissure, and specific cardiac conditions like coronary microvascular dysfunction.

Specific Trial Findings

Recent randomized clinical trials have explored the drug's effect in specific patient populations:

  • Angina and Vasomotor Dysfunction: One trial in patients with angina and nonobstructive coronary artery disease (ANOCA) found that diltiazem therapy did not substantially improve overall coronary vasomotor dysfunction or quality of life over six weeks compared to placebo. However, a reduction in the prevalence of epicardial spasm was observed in the diltiazem group.
  • Hypertension: Dose-response studies in essential hypertension patients reported that increasing doses were associated with corresponding reductions in diastolic blood pressure compared to placebo.
  • Long-Term Data: Long-term follow-up studies and meta-analyses continue to support the drug’s role in managing chronic angina, often showing persistent improvements in exercise performance over several months without evidence of major safety shifts in the observed population.

All evidence is interpreted with the understanding that regulators approve indications, not study conclusions, and individual outcomes may vary.

Frequently Asked Questions (FAQ)

Common questions about Dilizem (FAQ)

Q: Does Dilizem affect kidney function over time?

Official product information states that Diltiazem is primarily metabolized by the liver. For this reason, official information indicates that dose adjustments are generally not required based solely on renal function. The prescribing information advises that monitoring of kidney function may be part of standard care during prolonged use of the medication.

Q: Are there certain foods or drinks to avoid while using Dilizem?

Official regulatory warnings advise limiting or avoiding excessive consumption of grapefruit or grapefruit juice. This is because substances in grapefruit can interfere with how the body breaks down Diltiazem, which may lead to increased levels of the drug in the bloodstream.

Q: Is Dilizem known to cause any long-term side effects?

The official safety profile for Diltiazem documents all known adverse effects reported during clinical trials and post-market surveillance. Regulatory agencies continuously monitor this full safety profile, ensuring that all reported safety concerns, whether acute or long-term, are contained within the official product documentation.

Q: Does Dilizem affect athletic performance or exercise tolerance?

Clinical studies in specific patient populations, such as those with ischemic heart disease, have evaluated the effect of Diltiazem on exercise tolerance. Official information indicates that the medicine functions by reducing the product of heart rate and blood pressure for a given workload during physical activity.

Q: What is the expected duration of effect for a single dose of Dilizem?

The extended-release formulations are designed to achieve a sustained therapeutic effect that allows for once-daily use. Official pharmacological data indicates that the medicine is absorbed throughout the dosing interval, with peak concentration levels in the bloodstream typically reached between 10 and 14 hours after administration.

Q: What are the signs of a serious, but rare, side effect from Dilizem?

Regulatory documents list certain serious, though rare, signs that have been reported while using Diltiazem. These include unexplained or sudden weight gain, persistent changes in mental status or mood, fainting, or a new slow, irregular, or pounding heartbeat.

Q: What is the purpose of the extended-release formula of Dilizem?

The extended-release (ER) formulas are designed to achieve a continuous, sustained therapeutic effect over a prolonged period. This formulation is intended to support a regimen where the medicine is taken only once daily, which simplifies the long-term management of chronic conditions such as hypertension and angina.

Q: Does Dilizem cause weight gain?

Weight increase has been reported as an adverse event in official safety documents. Official information notes that unexplained or sudden weight gain may occur, which is often related to fluid retention (edema) and is listed as a symptom that requires professional monitoring.

Q: Can Dilizem be taken with blood thinning medication?

Official safety information includes reports of increased bleeding time in some patients using Diltiazem. For this reason, caution is generally indicated when the medicine is combined with others that are known to affect blood clotting or coagulation.

Q: Does Dilizem interact with common pain relievers like ibuprofen?

According to official drug-drug interaction information, pain relievers classified as nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may reduce Diltiazem’s blood pressure-lowering effects. This potential interaction may necessitate closer professional monitoring of blood pressure.

Q: How quickly should I expect Dilizem to start working?

The extended-release form is detectable in the bloodstream within approximately two hours of taking a dose. However, the full therapeutic benefit for chronic conditions is assessed gradually over time, with any necessary dose adjustments typically made at intervals of 7 to 14 days.

Q: Is Dilizem safe to use during pregnancy, according to official information?

The official Pregnancy Risk Summary states that published literature has not identified a drug-associated risk of major birth defects or miscarriage in human pregnancies. However, animal studies conducted with doses higher than those recommended for humans suggested a potential risk for skeletal variations and embryofetal deaths.

Q: What does it mean if Dilizem is listed as an 'antagonist'?

Diltiazem is primarily classified by regulatory agencies as a calcium channel blocker or inhibitor. The term antagonist is also used in this context to mean that the medicine physically interferes with, or opposes, the natural action of calcium ions in the cells of the heart and blood vessels.

Q: Can people with diabetes use Dilizem?

Official adverse event reports indicate that Diltiazem has been associated with hyperglycemia (elevated blood sugar). Due to this potential effect, monitoring of blood glucose levels may be necessary for some patients, particularly those with pre-existing conditions like diabetes.

Q: What should I do if I feel like the medicine isn't working?

Official dosing instructions state that dose adjustments for chronic oral therapy are generally made over intervals of 7 to 14 days to determine effectiveness. If the desired therapeutic effect is not achieved, consultation with the prescribing clinician regarding dose adjustment (titration) is recommended.

Q: Can I take it with asthma?

According to the official safety labeling and contraindications for Diltiazem, common respiratory conditions such as asthma are not listed among the medical conditions that strictly prohibit the use of this medicine.

Q: Can using Dilizem cause changes in mood or anxiety levels?

Official regulatory adverse event reports include listings under the Nervous System section for potential changes in mood. Specifically, side effects such as depression, nervousness, and personality change have been reported in patients using this medicine.

Q: Why is Dilizem sometimes prescribed along with other blood pressure medicines?

Diltiazem has a balanced mechanism, affecting two key cardiovascular areas: it helps control heart rate and rhythm, and it reduces resistance in the blood vessels. This dual action makes it a common component of combination therapy alongside other medicines to address multiple factors that contribute to high blood pressure.

Q: What are the risks of stopping Dilizem suddenly?

Regulatory warnings related to the antihypertensive drug class state that sudden discontinuation of treatment may result in a rapid return of high blood pressure, sometimes referred to as a rebound effect. This change may be accompanied by symptoms related to increased sympathetic nervous system activity.

Q: Is there a link between Dilizem and skin sensitivity to the sun?

Photosensitivity, which is an increased skin sensitivity to exposure from the sun, has been reported as a dermatological adverse event in the postmarketing experience section of official labeling.

Q: Does Dilizem interact with common herbal products like St. John's Wort?

Official interaction information highlights substances that affect the CYP3A4 enzyme system. As Diltiazem is metabolized through this system, co-administration with known inducers of this enzyme, such as St. John's Wort, is generally cautioned against due to the potential for reduced effectiveness of Diltiazem.

Q: What does the term 'contraindication' mean in relation to Dilizem?

In regulatory terms, a contraindication is a condition or factor that makes the use of a medicine strictly prohibited. For Diltiazem, this means patients with specified medical conditions—such as severe hypotension or certain heart rhythm disorders—must not use the drug due to the high risk of serious adverse consequences.

Q: Can I drive or operate machinery while taking Dilizem?

Regulatory warnings advise patients to be cautious about engaging in hazardous activities, including driving or operating heavy machinery. This caution is issued due to common side effects like dizziness and somnolence (drowsiness), which may affect a person's ability to perform such tasks safely.

Q: Is a metallic taste in the mouth a common side effect of Dilizem?

Official adverse event reports list dysgeusia as a gastrointestinal side effect. Dysgeusia is the clinical term for a distortion or change in the sense of taste, which can sometimes manifest as a metallic taste in the mouth.

Q: Are there different strengths of Dilizem available?

The official dosage forms and strengths section confirms that Diltiazem is available in a variety of strengths to suit different clinical needs. These strengths vary depending on the specific formulation being used (e.g., immediate-release tablet or extended-release capsule).

Q: Can Dilizem cause sleep disturbances or insomnia?

Official regulatory adverse event reports include insomnia (difficulty sleeping) and abnormal dreams under the Nervous System/Psychiatric adverse events section.

How should Dilizem be stored and disposed of?

The official regulatory requirements for storing and disposing of Diltiazem hydrochloride are designed to ensure its stability and prevent accidental exposure.

Official Storage and Handling

Labeled Storage Temperature Requirements Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Permitted excursions: 15 C to 30 C (59 F to 86 F).
Environmental/Handling Constraints Do not freeze. Protect from light and excessive humidity.
Packaging Requirements Store in a tight, light-resistant container with a child-resistant closure.
Child-Protection Rule Keep this and all drugs out of the reach of children.

Disposal Instructions

Disposal of unused or expired Diltiazem must follow local waste disposal regulations. It is officially recommended to consult a pharmacist or local waste disposal service for guidance. Do not flush the medication down a drain or toilet unless specifically instructed to do so by the manufacturer's labeling, as disposal must comply with environmental protection legislation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dilizem found in:

A-Z Index: